Research Article Details
| Article ID: | A50748 |
| PMID: | 35278877 |
| Source: | Biochem Biophys Res Commun |
| Title: | Aerobic exercise improves non-alcoholic fatty liver disease by down-regulating the protein expression of the CNPY2-PERK pathway. |
| Abstract: | Non-alcoholic fatty liver disease (NAFLD) is highly prevalent, and physical exercise represents one of the most effective methods to attenuate NAFLD. However, the mechanism of aerobic exercise improving NAFLD remains unclear. This study aims to investigate the effect of aerobic exercise on CNPY2-PERK pathway in mice with NAFLD. Our study found that a high-fat diet induced NAFLD, causing an abnormal lipid metabolism and liver function injury, and increased the expressions of CNPY2, CNPY2 mRNA, PERK, PERK mRNA, p-eIF2a and CHOP. However, aerobic exercise reversesd all these parameters. These data suggest that CNPY2-PERK pathway is involved in the formation of NAFLD, and aerobic exercise can effectively improve NAFLD, which may be related to down-regulate the protein expressions of the CNPY2-PERK pathway. |
| DOI: | 10.1016/j.bbrc.2022.03.008 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S08 | Lifestyle measures | Lifestyle intervention; weight loss; diet adaptation; dietary interventions; lifestyle modifications; Exercise | -- | -- | Details |
| S02 | Enhance lipid metabolism | triglyceride-lowering; lipid tolerance; lipid metabolism | 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitor; Decreases intestinal cholesterol absorption; FXR agonist; ACC inhibitor; FAS inhibitor; DGAT2 inhibitor; SCD-1 inhibitor | Atorvastatin; Ezetimibe; Obeticholic Acid; GS-9674; GS-0976; TVB-2640; IONIS-DGAT2rx; Aramchol; | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|